# Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

> **NCT07390968** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 56 (estimated)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 mRNA Vaccine ARCT-021
- **BIOLOGICAL:** Tozinameran
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT07390968
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390968, "Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07390968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*